Cardiovascular Diseases Clinical Trial
To statistically examine cardiovascular disease (CVD) risk in different populations based on data from studies representing national samples, cohort studies, and clinical trials.
BACKGROUND:
Several algorithms have been developed to calculate multivariate risk of CVD based on
characteristics associated with the disease. Framingham Heart Study data were used to
develop the original algorithms, along with later models, using different mathematical
forms, outcomes, and characteristics. Researchers then began to investigate the issue of
generalizability, whether these risk estimates could be applied to new populations. For
these algorithms to have general application, they must be able to rank risk correctly. And,
when Framingham models were compared to new models developed for other studies, resulting
orderings of risk were, in fact, similar.
The ability to order risk correctly, however, does not imply that estimated probabilities
are right in terms of predicting disease for individuals. Methods are needed to assess
individual risk to make treatment decisions, do cost-benefit analyses, and quantify
benefits. These methods must be based on the patient's absolute risk, and existing equations
may be incapable of establishing absolute risk across populations.
Earlier comparisons of multivariate risk among studies have made comparison populations as
homogenous as possible before analysis. However, if multivariate risk estimates are to be
truly useful, they must be applicable to the general population, and to be applicable,
estimates must be based on comparisons of cohorts that include women and ethnic minorities.
Also, in statistical terms, estimates must be robust enough to allow for minor shifts in
methodologies for data collection and endpoint definition.
DESIGN NARRATIVE:
The heterogeneity of multivariate risk in different populations was examined based on data
from studies representing national samples, cohort studies, and clinical trials. An analysis
of these studies was conducted that included both sexes, various risk profiles, and
representatives from several nationalities and ethnic groups. The pooled sample involved 20
studies, 233,833 participants, and over 47,000 deaths. Based on a common statistical
approach, proportional hazards models were developed for each study to relate a set of
essential characteristics to the prediction of CVD mortality. The characteristics included
body mass index, age, blood pressure, serum cholesterol, smoking, and diabetes status. The
models were then compared in terms of their ability to predict absolute risk of mortality
across studies.
Secondary analyses were conducted to discover factors associated with inaccurate prediction
and study characteristics associated with particular findings, such as interaction terms. An
empirical examination was conducted of methods for adding newly discovered risk factors to
existing prediction equations.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|